FDA's Shift from Announcements to Action: Limited Rulemaking Amid Increased Media Presence

FDA's Unconventional Approach to Regulations Under Scrutiny

In a move that has raised eyebrows, the Food and Drug Administration (FDA) has been taking an unconventional approach to regulations under the Trump administration. Health Secretary Robert F. Kennedy Jr. recently announced plans to "phase out" synthetic food dyes, a move that has been met with skepticism by experts.

According to the FDA, the agency has reached an understanding with foodmakers to voluntarily stop using petroleum-based food dyes. However, the specifics of the plan remain unclear, and the FDA has yet to introduce any scientific regulatory documents to support the decision.

The FDA's handling of food dyes reflects a broader trend of the administration's approach to health priorities. Instead of using the traditional process of federal rulemaking, officials have opted for a quicker approach: announcing sweeping changes first and dealing with the regulations later.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Critics argue that this approach is problematic, as it bypasses the usual process of consulting with experts and allowing for public comment. "It speaks volumes that the administration has yet to produce a document articulating the scientific basis for the voluntary request," said Susan Mayne, a Yale University public health expert and former director of the FDA's food program.

The FDA's website continues to carry the government's longtime conclusion that "the totality of scientific evidence" does not show a link between synthetic dyes and health problems. However, if the FDA has changed its position, it should document why and pursue a ban, according to Mayne.

The lack of initiative in drafting new regulations is particularly striking at the FDA. Under federal law, the agency is supposed to refrain from making major policy announcements in news releases, speeches, or other informal settings. However, a string of changes from FDA Commissioner Marty Makary and his deputies have appeared first in medical journal op-eds, television interviews, or online posts.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

One of the biggest changes came last May, when Makary and then-FDA vaccine chief Dr. Vinay Prasad published a medical journal article announcing that the FDA would no longer routinely approve COVID-19 shots for healthy adults under age 65 and children without underlying health problems. To win approval for that group, vaccine manufacturers would need to conduct large studies that many experts say may not be feasible in today's post-pandemic environment.

The FDA's shift away from rulemaking has been met with little resistance from the powerful companies it regulates. "Does the government have the ability to basically bully companies?" asked Dan Troy, the FDA's former chief counsel. "Yes, and I think we're seeing that."

One of the biggest changes came last May, when Makary and then-FDA vaccine chief Dr. Vinay Prasad published a medical journal article announcing that the FDA would no longer routinely approve COVID-19 shots for healthy adults under age 65 and children without underlying health problems.

The lack of pushback from vaccine manufacturers may reflect the tremendous power the FDA holds over them. "Ultimately, you need the FDA to license your product," said Dr. Kathryn Edwards, a retired vaccine scientist at Vanderbilt University. "If you're going to try and buck the FDA -- especially in this environment -- the likelihood of your product getting a positive review is going to be pretty low."

The FDA's unconventional approach to regulations has also raised concerns about the lack of transparency and accountability. "Anything that this administration does that they don't embody in law can easily be undone by a future administration," said Troy.

Despite these concerns, there are signs that at least some companies may be willing to raise objections. The FDA last year began releasing rejection letters for drugs it declined to approve, and an unnamed drugmaker has filed a formal petition challenging the practice.